Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245712 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
A Phase 2 study of Invasive Breast Carcinoma and Breast Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT01245712: Active Phase 2 study of Invasive Breast Carcinoma and Breast Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT01245712 is a Phase 2 study of Invasive Breast Carcinoma and Breast Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01245712, a Phase 2 study of Invasive Breast Carcinoma and Breast Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Primary Outcome
Patient-reported cosmesis score on the Breast Cancer Treatment Outcomes Scale (BCTOS) at 1 year. Cosmesis scores range from 1 (excellent) to 4 (poor), and scores of 3 (fair) or more indicate adverse cosmetic outcomes.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- RADIATION Accelerated Partial Breast Irradiation
- RADIATION Proton Beam Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2010-11-15 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 2 |
What the registry record for NCT01245712 still lists
NCT01245712 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 481-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (58% lower).
The record links to 10 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT01245712 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01245712 about?
NCT01245712 is a clinical study titled "Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer". This phase II trial studies the side effects and how well radiation therapy works in treating patients with stage 0-II breast cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
What is the current status of trial NCT01245712?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2010-11-15. Estimated completion is 2032-12-31.
What conditions does trial NCT01245712 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT01245712?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Accelerated Partial Breast Irradiation (RADIATION), Proton Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01245712?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01245712 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01245712's enrollment target sits among peer trials
200 17th of 45 higher than 27 of 45 other Invasive Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Invasive Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI